<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01534221</url>
  </required_header>
  <id_info>
    <org_study_id>COPERNICOS</org_study_id>
    <nct_id>NCT01534221</nct_id>
  </id_info>
  <brief_title>The COOPerative Establishment for Necessary Investigation in Clinical Outcome After Stenting</brief_title>
  <acronym>COPERNICOS</acronym>
  <official_title>Randomized Comparison of Outcome of Stenting in Unselected Patients in Everyday Clinical Practice</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zealand University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zealand University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The superiority of a percutaneous coronary intervention (PCI) by one stent over another in&#xD;
      terms of clinical outcome is usually documented in large randomized controlled trials (RCT).&#xD;
      Although generated from selected study populations these data form the basis for evidence&#xD;
      based practice (EBP) in the entire population of patients considered for coronary&#xD;
      intervention. An inherent limitation of this approach is that study populations differ&#xD;
      significantly from all comers in terms of patient characteristics and prognosis undermining&#xD;
      the foundation for extrapolation of trial results to all comers. Furthermore, other trials&#xD;
      are based on a &quot;one-fits-all&quot; concept, while the benefits of an &quot;individual-tailored&quot;&#xD;
      approach that might be superior, is not investigated.&#xD;
&#xD;
      The Purpose of the current study is to&#xD;
&#xD;
        -  Compare clinical outcome between several CE marked drug eluting stents&#xD;
&#xD;
        -  Compare clinical outcome between several CE marked bare metal stents&#xD;
&#xD;
        -  Compare clinical outcome in all comers with that of the selected study population of&#xD;
           RCT's&#xD;
&#xD;
        -  Evolve methods to compare clinical outcomes between the generalized &quot;one-fits-all&quot;&#xD;
           versus the individualized or &quot;individual-tailored&quot; stent selection approaches&#xD;
&#xD;
      The Method employed is&#xD;
&#xD;
        -  All comer PCI registry - single centre&#xD;
&#xD;
        -  Randomisation of all eligible patients within the registry to one of several study stent&#xD;
&#xD;
        -  Quality assurance in non-randomized population within the registry by periodical&#xD;
           alternating the institutional standard stent&#xD;
&#xD;
        -  Continuous follow up of all patients included the registry by means of systematic event&#xD;
           detection and classification by an independent safety and end point committee&#xD;
&#xD;
        -  Assessment of effects on quality of life by heart and health questionnaires&#xD;
&#xD;
      Outcome Measures&#xD;
&#xD;
      Primary endpoints:&#xD;
&#xD;
        -  Composite of cardiac death, acute myocardial infraction and target vessel&#xD;
           revascularisation&#xD;
&#xD;
        -  Stent thrombosis&#xD;
&#xD;
        -  A specifically developed Treatment Failure Rate classification&#xD;
&#xD;
      Secondary outcome measures include each of the above, target lesion revascularisation and&#xD;
      total death analyzed in a hierarchical fashion at 2, 3, 4 and 5 years.&#xD;
&#xD;
      Tertiary outcome measure is self reported quality of life based on health questionnaires on&#xD;
      general health and cardiac symptoms.&#xD;
&#xD;
      Power Calculations An event rate of 20% within 5 years, a relative difference of 25% (an&#xD;
      absolute difference of 5%), P&lt; 5%, Power &gt; 80% =&gt; 900 patients in each of two treatment arms.&#xD;
&#xD;
      Prespecified Analysis include&#xD;
&#xD;
        1. The MACE rates between stent types&#xD;
&#xD;
        2. The Stent thrombosis rates between stent types&#xD;
&#xD;
        3. The Treatment failure rates between stent types&#xD;
&#xD;
        4. The randomized population versus non-randomized population&#xD;
&#xD;
        5. The individualized versus the generalized Population&#xD;
&#xD;
        6. QOL between stent types&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All MACE and stent thromboses are adjudicated by an independent end point and safety&#xD;
      committee chaired by Jørgen Jeppesen known from the very same task he executed in the SORT&#xD;
      OUT II.&#xD;
&#xD;
      Further question may be answered by the four key investigators:&#xD;
&#xD;
      Steen Carstensen, Anders Galløe, Ole Havndrup, Lars Kjøller-Hansen&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>March 2012</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MACE</measure>
    <time_frame>Five year</time_frame>
    <description>Major adverse cardiac events defined as a composite of cardiac death, acute myocardial infraction and target vessel revascularisation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stent thromboses</measure>
    <time_frame>Five year</time_frame>
    <description>Definite, propable and possible</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment failure</measure>
    <time_frame>Five Years</time_frame>
    <description>A specifically developed Treatment Failure Classification</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Death of any cause</measure>
    <time_frame>One and five years</time_frame>
    <description>Ongoing quality assurance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self reported health questionnaires on general health and cardiac specific symptoms.</measure>
    <time_frame>One and five years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac death</measure>
    <time_frame>One and five years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>One and five years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion revascularisation</measure>
    <time_frame>One and five years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel revascularisation</measure>
    <time_frame>One and five years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis</measure>
    <time_frame>One and five years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Failure</measure>
    <time_frame>One and five years</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">5100</enrollment>
  <condition>Ischemic Heart Disease</condition>
  <arm_group>
    <arm_group_label>Study group two</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Endeavor resolute drug eluting stent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study group three</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The precise selection of brand name depends on negotiations with suppliers and may change during the study period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study group four</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The precise selection of brand name depends on negotiations with suppliers and may change during the study period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study group five</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The precise selection of brand name depends on negotiations with suppliers and may change during the study period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study group one</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The precise selection of brand name depends on negotiations with suppliers and may change during the study period</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Biomatrix drug eluting stent</intervention_name>
    <description>Biomatrix drug eluting stent</description>
    <arm_group_label>Study group five</arm_group_label>
    <arm_group_label>Study group four</arm_group_label>
    <arm_group_label>Study group one</arm_group_label>
    <arm_group_label>Study group three</arm_group_label>
    <arm_group_label>Study group two</arm_group_label>
    <other_name>Biomatrix</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  to enter COPERNICOS registry for quality assessment: Each and every patient assigned&#xD;
             to percutaneous coronary intervention will be included.&#xD;
&#xD;
          -  to enter COPERNICOS randomization: If the patient fulfil the Helsinki declaration and&#xD;
             have a Danish personal security identification number they are asked to give written&#xD;
             informed consent to participate in the randomized study arms.&#xD;
&#xD;
        Exclusion Criteria to randomization:&#xD;
&#xD;
          -  unconscious patients&#xD;
&#xD;
          -  residents in other countries thereby escaping event detection&#xD;
&#xD;
          -  patients unable to understand the rationale of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anders M Galløe, Md.Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zealand University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steen Carstensen, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Zealand University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ole Havndrup, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Zealand University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lars Kjøller-Hansen, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Zealand University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gunnar VH Jensen, MD</last_name>
    <role>Study Director</role>
    <affiliation>Zealand University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jørgen Jeppesen, MD</last_name>
    <role>Study Director</role>
    <affiliation>Glostrup University Hospital, Copenhagen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anders M Galløe, MD.Ph.D.</last_name>
    <phone>+45 47 32 60 22</phone>
    <email>anders@galloe.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Steen Carstensen, MD.Ph.D.</last_name>
    <phone>+45 47 32 60 11</phone>
    <email>sct@regionsjaelland.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Roskilde County Hospital</name>
      <address>
        <city>Roskilde</city>
        <zip>4000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <contact>
      <last_name>Anders M Galløe, MD</last_name>
      <phone>+45 47 32 60 22</phone>
      <email>anders@galloe.dk</email>
    </contact>
    <contact_backup>
      <last_name>Steen Carstensen, MD</last_name>
      <phone>+45 47 32 60 11</phone>
      <email>sct@regionsjaelland.dk</email>
    </contact_backup>
    <investigator>
      <last_name>Anders M Galløe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Steen Carstensen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ole Havndrup, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lars Kjøller-Hansen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <study_first_submitted>January 30, 2012</study_first_submitted>
  <study_first_submitted_qc>February 15, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 16, 2012</study_first_posted>
  <last_update_submitted>February 15, 2012</last_update_submitted>
  <last_update_submitted_qc>February 15, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 16, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zealand University Hospital</investigator_affiliation>
    <investigator_full_name>Anders Galloe</investigator_full_name>
    <investigator_title>Consultant</investigator_title>
  </responsible_party>
  <keyword>Ischemic Heart Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

